Latest Marketable Securities News

Imricor Medical Systems has filed a Form 10 registration with the U.S. SEC, marking its transition to a U.S. reporting company amid ongoing FDA clearances and clinical trials. This move signals a significant step in its early commercialisation of MRI-guided cardiac ablation technology.

Dexus Convenience Retail REIT has extended its on-market securities buy-back program for another year, aiming to repurchase up to 2.5% of its securities to enhance shareholder value amid current trading conditions.

Dexus Industria REIT has announced an on-market securities buy-back targeting 2.5% of its issued securities, aiming to enhance returns for investors. The buy-back is set to commence from 24 March 2026 following a mandatory waiting period.

Dexus has announced a 19.3 cents per security distribution for HY26, aligned with its updated payout policy, alongside robust financial results and a strategic 10% on-market buyback to address valuation gaps.

ReNerve Limited reported a half-year loss of $2.72 million, up 47% from last year, as it expands its nerve repair product portfolio and secures new regulatory approvals in Asia-Pacific.

Imricor Medical Systems saw a sharp 69.5% decline in revenue for 2025, driven by clinical trial impacts, yet narrowed its net loss to $25.3 million as it secured FDA clearance for key products post-year-end.

Genesis Energy has completed a NZ$100 million share placement at NZ$2.15 per share, paving the way for a NZ$300 million rights offer to fund its renewable energy expansion under the Gen35 strategy.

Livium Ltd has turned a profit in the first half of FY26 despite lower revenues, supported by cost cuts and a new joint venture. The company also secured $4.5 million in fresh capital to expand its lithium-ion battery recycling and rare earth initiatives.

Dexus has announced a new on-market buyback of up to 10% of its securities, aiming to address the disconnect between its market valuation and underlying asset values while maintaining capital discipline.

SHAPE Australia Corporation Limited reported a robust half-year performance with a 48.5% rise in net profit and declared a fully franked 14 cent interim dividend, underpinned by strategic acquisition and operational discipline.

AVITA Medical reported a mixed fourth quarter with revenue pressures easing and full-year growth, underpinned by a new $60 million credit facility and advancing clinical trials.

AVITA Medical reported steady Q4 losses amid reimbursement challenges but achieved 11% revenue growth for 2025 and secured a $60 million credit facility to fuel future expansion.